Login
Companies $BVS
$10.46 -$0.20 (1.88%) Live
Bioventus Inc. logo

Bioventus Inc.

Compare classes
bioventus.com

What Do They Do?

Sells pain treatments, surgical devices and fracture-healing products to physicians, hospitals and patients.

How Do They Make Money?

The company sells medical products to healthcare providers, institutions, patients and distributors. Most products are billed at shipment or patient acceptance; hospitals are billed for consigned bone grafts when used in surgery.

revenue
SegmentShareRevenue
U.S.
Sold outright

88%
FY2022: 89%
International
Sold outright

12%
FY2022: 11%

Who Are Their Customers?

The company sells directly to healthcare institutions, patients and healthcare providers, and some surgical products reach hospitals through independent distributors. In certain international markets, distributors sell to physicians.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: no customer at 10% or more of revenue

Do Revenues Turn Into Profits?

Yes. It kept 4 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.

Operating income, FY2025
10% of revenue
▲ Turned profitable vs FY2024 (−$15.2M, −3%)
Net income, FY2025
4% of revenue
▲ Turned profitable vs FY2024 (−$36.1M, −6%)
Free cash flow, FY2025
13% of revenue
▲ +91% vs FY2024 ($37.8M, 7%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 26, 2026
Revenue
▲ +3%
vs $138.7M in Q3 FY2025
Net income
▲ +90%
vs $3.2M in Q3 FY2025
U.S. Segment share of revenue vs 88.9% in Q3 FY2025
  • Aug 5, 2026 Started a strategic review after receiving acquisition interest An independent committee is assessing options, including a sale or continuing as a standalone company; it also reaffirmed revenue, adjusted earnings-per-share and operating cash flow guidance for 2026.

Growing. Revenue grew 32% in 4 years, from $430.9M in FY2021 to $568.1M in FY2025, about 7% a year.

New nerve-stimulation products The older report described TalisMann as still in development and not cleared; the latest says TalisMann and StimTrial were cleared and began limited sales.

Restorative portfolio narrowed The older report described restorative therapies as including devices to restore leg or hand function; the latest reports the sale of Advanced Rehabilitation and describes restorative therapies around fracture care.

Revenue over time
U.S. International
$1B$500M$0

Who Do They Compete With?

Competes with Ferring Pharmaceutical, Fidia Farmaceutici, Johnson & Johnson, Zimmer Biomet Holdings, Arthrex, Emcyte, Channel-Markers Medical, SPR Therapeutics, Nalu, Curonix, Medtronic, DePuy Orthopaedics, Stryker, NuVasive, Orthofix Medical, Globus Medical, Integra Life Sciences, Söering, Enovis, and XFT Medical

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support